- Home
- PACS vs MYGN Comparison
PACS vs MYGN Comparison
Compare PACS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PACS
- MYGN
- Stock Information
- Founded
- PACS 2013
- MYGN 1991
- Country
- PACS United States
- MYGN United States
- Employees
- PACS N/A
- MYGN N/A
- Industry
- PACS
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PACS
- MYGN Health Care
- Exchange
- PACS Nasdaq
- MYGN Nasdaq
- Market Cap
- PACS 2.1B
- MYGN 2.0B
- IPO Year
- PACS 2024
- MYGN 1995
- Fundamental
- Price
- PACS $13.81
- MYGN $12.39
- Analyst Decision
- PACS Strong Buy
- MYGN Hold
- Analyst Count
- PACS 9
- MYGN 12
- Target Price
- PACS $33.22
- MYGN $23.92
- AVG Volume (30 Days)
- PACS 602.3K
- MYGN 1.0M
- Earning Date
- PACS 02-16-2025
- MYGN 02-25-2025
- Dividend Yield
- PACS N/A
- MYGN N/A
- EPS Growth
- PACS 82.79
- MYGN N/A
- EPS
- PACS 0.68
- MYGN N/A
- Revenue
- PACS $3,558,953,000.00
- MYGN $823,600,000.00
- Revenue This Year
- PACS $29.04
- MYGN $13.82
- Revenue Next Year
- PACS $18.31
- MYGN $4.59
- P/E Ratio
- PACS $20.30
- MYGN N/A
- Revenue Growth
- PACS 205.08
- MYGN 12.15
- 52 Week Low
- PACS $12.54
- MYGN $12.17
- 52 Week High
- PACS $43.92
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- PACS N/A
- MYGN 29.80
- Support Level
- PACS N/A
- MYGN $12.17
- Resistance Level
- PACS N/A
- MYGN $15.08
- Average True Range (ATR)
- PACS 0.00
- MYGN 0.79
- MACD
- PACS 0.00
- MYGN -0.01
- Stochastic Oscillator
- PACS 0.00
- MYGN 7.56
About PACS PACS Group Inc. Common Stock
PACS Group Inc is a post-acute healthcare company primarily focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.